Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Sarcopenia and high MELD scores independently predict poor survival in advanced liver cancer patients treated with Sorafenib. A combined SARCO-MELD score identifies patients with significantly worse outcomes.
Area Of Science
- Hepatology
- Oncology
- Radiology
Background
- Sarcopenia is linked to adverse outcomes in cirrhosis and hepatocellular carcinoma (HCC).
- The prognostic value of sarcopenia in advanced HCC patients receiving Sorafenib remains unclear.
Purpose Of The Study
- To evaluate the impact of sarcopenia on survival in advanced HCC patients treated with Sorafenib.
- To identify prognostic factors for survival in this patient cohort.
Main Methods
- Retrospective analysis of 328 advanced HCC patients.
- Abdominal CT scans used to calculate skeletal muscle index at L3 level for sarcopenia definition.
- Patients divided into Training (215) and Validation (113) cohorts.
Main Results
- Sarcopenia was present in 48% (Training) and 50% (Validation) of patients.
- Sarcopenia and MELD score > 9 were independent negative prognostic factors in both cohorts (HRs ranging from 1.47 to 1.99).
- The novel SARCO-MELD score, combining these factors, stratified patients into three groups with significantly different survival rates.
Conclusions
- Sarcopenia is a significant independent predictor of poor survival in advanced HCC patients treated with Sorafenib.
- The SARCO-MELD score effectively predicts survival and can aid in treatment decisions.
- Integrating sarcopenia assessment into clinical practice may improve patient management.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...